貝達藥業(300558.SZ):丁師哲擬增持60萬股-100萬股 今日已增持54.4萬股
格隆匯3月8日丨貝達藥業(300558.SZ)公佈,公司於今日收到股東丁師哲的通知,丁師哲於3月8日通過契約型私募基金的方式在深交所交易系統以集中競價方式增持公司股份54.4萬股(佔公司總股本的0.13%),交易均價為55.1340元/股。丁師哲系公司實際控制人、董事長兼CEO丁列明的直系親屬。
自該公吿披露之日起6個月內,丁師哲計劃通過契約型私募基金的方式在深交所交易系統以集中競價方式累計增持數量不低於60萬股,不超過100萬股(含今日已增持的54.4萬股);增持不設定價格區間,將根據公司股票價格波動情況以市場價格擇機增持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.